We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New, Easy-To-Use CRISPR-Based HIV Test Kit to Deliver Results in Minutes

By LabMedica International staff writers
Posted on 11 Jul 2024

With 1. More...

3 million new HIV cases and 630,000 HIV-related deaths reported in 2022 by the World Health Organization, improving and simplifying HIV detection in patients is crucial for reducing outbreaks and the resultant deaths. Although home testing kits for various health conditions have gained popularity, advancements in HIV testing have been slower to develop. Traditional HIV tests typically only become effective several weeks post-infection, raising the risk of unintentional virus transmission. Now, an innovative HIV-detection test kit utilizing advanced CRISPR technology is under development and could act as an early-warning system, potentially saving millions of lives.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, represents a breakthrough in genetic engineering, allowing selective modifications to the DNA of organisms in lab environments. This technology leverages genome editing systems that occur naturally in bacteria. A research team at the University of Florida (Gainesville, FL, USA) is nearing completion of their HIV detection method that employs CRISPR technology. Promising rapid results, this test could enable earlier treatment for patients, potentially reducing viral loads to undetectable levels.

The innovative CRISPR-based kit is designed to measure HIV RNA levels quickly using a compact microfluidic device. This palm-sized prototype facilitates rapid self-testing soon after potential exposure, delivering results within minutes. With additional development, this self-testing kit could be available for use in various settings, including homes, doctor's offices, community clinics, and outreach locations like homeless shelters, within the next five years. The team's initial research into this HIV testing method has yielded encouraging results.

“Our goal is to develop a test kit that is not only highly advanced but also user-friendly, like a reliable alarm that detects potential issues before they escalate,” said Piyush Jain, Ph.D., an assistant professor at UF’s Department of Chemical Engineering, who is leading the research team. “This research is crucial given the staggering global impact of HIV and the critical need for early detection.” 

Related Links:
University of Florida


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.